shown to have similar biologic properties to the androgen-independent (AI) prostate cancer.
The outcome of this study can improve the current treatment strategy for AI prostate cancer.
Structurally, C-CAM1 is a cell adhesion molecule with receptor kinase motif in the C-terminus.
Together with DOC-2, a typical signal molecule, we believe that both genes play an important role in controlling the growth and differentiation of prostatic epithelia.
Our results indicate that both C-CAM1 and DOC-2 are down-regulated in AI prostate cancer and increased expression of individual gene can inhibit cancer growth.
We have further defined the functional domain in both genes which modulate their tumor suppression activities.
More detailed analyses are underway for C-CAM1 protein. For DOC-2 protein, it appears that DOC-2 can interact with an novel protein that belongs to the Ras GTPase-activating protein (GAP) family.
Ras-GAP is a key factor to maintain the balance of both active and inactive status of Ras protein.
Our finding signifies the critical role of DOC-2 in prostate development and carcinogenesis. 14 
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INTRODUCTION
The purpose of this study is to define the signaling pathways which control growth and differentiation of prostatic epithelia. Homeostatic factor(s) that operate in the androgen-independent (AI) basal cell population of the prostate can modulate the stimuli for extracellular growth by regulating particular gene(s) expressed in the nucleus. Genes with a potent growth inhibitory effect on prostate cancer, C-CAM1 and DOC-2, were chosen for the study because C-CAM1 behaves like a membrane receptor and DOC-2 is a signaling molecule. Moreover, both are novel genes, which have recently been reported by this laboratory. To delineate the signaling network elicited by these genes, three aims were proposed: 1) to specify the interaction of C-CAM1 and DOC-2 during development of the prostate and of carcinogenesis; 2) to identify the signaling pathway elicited by these putative homeostatic molecules; and 3) to document the effect of microenvironmental factors on the regulation of these molecules. Recurrent Al prostate cancer has been shown to possess many similar characteristics with the population of Al basal cells in the normal prostate. Thus, the larger purpose of this study is to apply the knowledge gained to develop an effective regimen to treat Al prostate cancer.
RECENT PROGRESS
The study had progressed smoothly in the past year. One manuscript has been published (Appendix 1); a second is in preparation. Overall, Task 1 is nearly completed, Task 2 is 50% completed, and work on Task 3 will begin shortly. Detailed progress of these aims is outlined below.
Task 1.
To specify the interaction of C-CAM1 and DOC-2 during development of the prostate and of carcinogenesis.
Recently, we demonstrated that expression of C-CAM1, an immunoglobulin (Ig)-like CAM, correlates with androgen-induced prostate epithelial differentiation in an organ-specific manner (1) . Constitutive expression of the C-CAM protein was detected in normal prostatic epithelium throughout the fetal to adulthood stage (2) . However, C-CAM expression was diminished in both prostate intraepithelial neoplasia and cancer lesions (2) , which indicates that loss of C-CAM expression may be involved in the early stages of prostate carcinogenesis. In addition, increased C-CAM expression, through gene transfection or delivery of recombinant adenovirus, can effectively control growth of prostate cancer both in vitro (3) and in vivo (4) . According to sequence analysis of C-CAM 1 cDNA, C-CAM1 represents a unique CAM with a potential signal transducing capability. Therefore, the relationship of each C-CAM structural domain that could possibly affect its tumor suppression function in vivo was analyzed using a variety of mutants -ranging from deletion mutation of the extracellular domain to the intracellular domain. Because of its high infectivity, an adenoviral vector system was employed as a delivery sytem. Data from in vivo tumorgenic assay indicated that the C-CAM mutant without cell adhesion function retained its tumor suppressive activity. In contrast, deletion in the Ser/Thr phosphorylation site but not in the tyrosine phosphorylation site of C-CAM 1 resulted in the loss of tumor suppressive activity. These data suggest that, in contrast to the extracellular domain, the potential Ser/Thr phosphorylation site in the intracellular domain of the C-CAM molecule and its associated protein(s) are crucial for the suppression of the growth of prostate cancer (see Appendix 1).
Elevated levels of DOC-2 mRNA and protein are detected in the degenerated prostate (5). Immunohistochemical staining indicates that both DOC-2 and C-CAM I proteins are associated with the enriched basal cells in the prostate (1, 5) . Furthermore, restored expression of DOC-2 can inhibit the growth of prostate cancer (5) . It is likely that both proteins have an interaction. So, to further delineate the possible interaction between DOC-2 and C-CAM1, a co-immunoprecipitation experiment was conducted by transfecting both DOC-2 and C-CAM1 expression vectors. As Fig. 1 demonstrates (Appendix 2), no physical interaction between these proteins can be detected. This suggests that DOC-2 and C-CAM 1 proteins may not contact directly.
Task 2.
To identify the signaling pathway elicited by these putative homeostatic molecules.
Our previous data demonstrated that the presence of an unknown factor(s) was associated with DOC-2 protein by immunoprecipitation. We used a yeast two-hybrid system (6) to search for these factors. Initially, the bait vector was constructed from pVJL1 1 by inserting the N-terminus of DOC-2 protein (i.e., residues 1-269), which had been demonstrated to the major protein phosphorylation site in DOC-2. Among an estimated 9X10 4 clones plated for screening, 94 clones with His+ phenotype were obtained. But, only 34 clones appeared positive in both His and LacZ phenotypes. After screening with mating test to rule out false positive results, 3 independent clones, DIP1 (1.7 kb), DIP2 (5.5 kb), and DIP7 (2.8 kb) were confirmed. Further cDNA sequencing and alignment (Appendix 3) suggest these clones belong to, and are novel members of, the GTPase activating protein (i.e., GAP) family. The sequence alignment data also suggests that these clones share some homologue with the C-terminal of the GAP sequence that is known to interact with RAS-protein (7). The DIP1 and DIP2 sequences overlapped, which indicates that both derive from the same cDNA species.
To unveil their expression pattern in different tissues and organs, and to demonstrate each clone's distinct pattern, northern analysis ( Fig. 2A in Appendix 2) was performed. For example, DIP7, with a major 6.0 kb transcript, appears to be brain-specific, while DIP1 and DIP2, with at least two transcripts (7.0 kb and 4.7 kb), appear present in brain, kidney, and both prostatic epithelial and stromal cell cultures. This suggests that at least two groups of DIPs are present in brain and other tissues. Interestingly, DIP 1/2 was detected in prostatic epithelial cells derived from the basal cells (e.g., NbE and VPE), but it was not detected in intact VP because the basal cell population constitutes only 5% of the total prostatic epithelia in intact VP.
After screening another brain cDNA library, we were able to assemble a full-length cDNA of DIP1/2. As , in contrast to preimmune serum, the polyclonal antibody can specifically recognize a 130 kD protein derived from in vitro translation of DIP 1/2 cDNA. In the rat brain we observed several additional protein bands that may be produced by protein modification and/or isoform. The polyclonal antibody should be a specific antibody against DIP1/2. Thus far we have used this antibody to determine whether DIP1/2 protein interacts with the C-CAM1 protein.
A similar approach using a yeast two-hybrid system was employed to identify the presence of the downstream effector for the C-CAM1 protein because our laboratory is experienced with this methodology and because this system provides a swift way to clone any cDNA sequence. A bait vector containing the intracellular domain of C-CAM1 is under construction. When it is finished, this bait vector will be subjected to the same screening procedures used in the DOC-2 experiment.
KEY RESEARCH ACCOMPLISHMENT
"* Dissociated the Ig domain (for adhesion activity) of the C-CAM 1 protein with its tumor suppression activity.
"* Determined the functional domain of the C-CAM1 protein (i.e., intracellular domain) for its tumor suppression activity.
"* Demonstrated that there are no direct interaction between C-CAM 1 and DOC-2 proteins.
"* Identified a novel gene (i.e., DIP1/2) from Ras-GAP family as a downstream effector of DOC-2 protein.
3
"* Cloned a full-length DIP1/2 cDNA and generated a specific antibody for DIP1/2 protein. 
CONCLUSIONS
The basal cells of the prostate gland, considered as a stem cell population, are not only responsible for maintaining homeostasis of the normal prostate but also contribute to the progression of Al prostate cancer. Until now, the regulatory pathway(s) involved in prostate homeostasis was undefined. In this study we have examined: 1) the functional role of two unique basal cell-associated genes, C-CAM1 and DOC-2, in Al prostate cancer, and 2) the signaling network elicited by these two genes.
We were able to define the intracellular domain containing a Ser/Thr phosphorylation site as a key domain to modulate the tumor suppression function of the C-CAM1 protein (Appendix 1). Our results clearly indicate that the C-CAM1 protein can function like a membrane receptor in order to initiate a cascade of phosphorylation events through a variety of adapter proteins and kinases, which subsequently culminate in a wave of immediate early gene expression in the nucleus. Therefore, because we have ruled out any possible interaction between C-CAM1 and DOC-2 proteins, the immediate study is to identify the effector protein(s) associated with DOC-2 protein.
We have shown that DOC-2 can suppress the in vitro growth of prostate cancer cells (5) . In our recent study, we demonstrated that phosphorylation of serine 24 in the N-terminus of the DOC-2 protein correlates with its activity (6) . Using the yeast two-hybrid screening system we identified a novel gene, DIP1/2, belonging to the Ras-GAP family, as an immediate interactive protein for DOC-2. DIPl/2 appears to express in many tissues, including degenerated prostates and prostatic epithelial cell cultures derived from the basal cell population. Further characterization of the function role of DIP1/2 in signal transduction and the regulation of DIP1/2 by microenvironmental factors will certainly unveil the signal cascade that controls the growth and differentiation of prostatic epithelium.
This study signifies the potential role of homeostatic factors in the progression of prostate cancer. These new molecules may serves as surrogate markers for predicting the biologic behavior of prostate cancer. Moreover, the information gleaned from this study can be used to formulate a new regimen able to intervene sooner during the multiple steps of prostate carcinogenesis.
5.
Tseng, C-P., Ely, B., Pong, R-C., Li, Y., and Hsieh, J. studies, we demonstrated that an androgen-repressed assay as follows: AdCAM101 (3.4 x 1010 pfu/ml); CAM [1] , C-CAM1, was inversely correlated with the AdCAM902 (1.1 x 101l pfu/ml); AdCAMAD1 (1.8 x status of premalignant lesions of human prostate can-1010 pfu/ml); AdCAMF488 (4.0 x 101° pfu/ml); cer, i.e., prostate intraepithelial neoplasia, and cancer AdCAMG454 (3.9 x 101" pfu/ml); and AdCAMH458 lesions as well, indicating that C-CAM1 may be a po-(1.3 x 101° pfu/ml). tent tumor suppressor in prostate carcinogenesis [2] .
In this study, we used both adenoviral DNA and To demonstrate the tumor-suppressive function of Cviral infectivity to characterize each recombinant ad-CAM1, we transfected a high-tumorigenic prostate enovirus. To confirm the presence of the cDNA insert, cancer line (PC-3) with a C-CAM1 expression vector recombinant adenoviral genomic structure was car- [3] , or infected PC-3 cells with a recombinant adenoried out using the polymerase chain reaction (PCR), as virus expressing C-CAM1 cDNA [4] . In both cases, described previously [4] . In the PCR reaction, three both the in vitro and in vivo growth of prostate cancer sets of primer were used separately: primer set B [6] cells was significantly inhibited. In addition, by dewas used for identifying the presence of the cDNA creasing endogenous expression of C-CAM levels in a insert; primer set C [6] was used for identifying the nontumorigenic prostatic epithelium cell line with an presence of viral sequences; primer set D [ 5 'ATTACantisense vector resulted in an increase of the in vivo CGAAGAAATGGCCGC 3 ', 5 'CCCATTTAACACGCtumorigenicity of this cell line [3] . Therefore, C-CAM CATGCA 3 '] [7] was used for examining the presence is a potent tumor suppressor in human prostate canof the El region. On the other hand, viral infectivity cer.
was determined in the PC-3 cells 24 hr after viral inBased on cDNA sequences, the structure of the Cfection by fluorescent-activated cell scanning (FACS) CAMI molecule is very similar to that of the carcinoanalysis, as described previously [4] . embryonic antigen (CEA) and belongs to the immunoglobulin (Ig) gene superfamily. However, C-CAM1
Determination of Viral Infectivity of PC-3 Cells by represents a new family of Ca 2 +-independent CAMs Fluorescent-Activated Cell Scanning Analysis because it contains three distinct domains, i.e., the extracellular, the transmembrane, and intracellular do-Pel eeifce ihdfeetvrssa mains. The first Ig loop in the extracelluar domain is 100 m.o.i. (multiplicity of infection) and incubated at critical frThe finstercelllarp adhes oftr r C oCaMn [5is.
37'C for 24 hr. Immunofluorescence staining was carcritical for the intercellular adhesion of C-CAM1 [5] .
ried out as described previously [4] , and then the perAlso, the transmembrane domain is required for Cne ou as dese v l4 nd te t per-CAM1 as a cell surface molecule. Interestingly, the centage of positive cells was determined by a dualcytoplasmic (or intracellular) domain with 71 amino laser Vantage flow cytometer (Becton Dickinson, acids contains at least two potential phosphorylation Mountain View, CA). sites, including one for cAMP-dependent kinase and tyrosine kinase, suggesting that C-CAM1 may funcdet ion of C CAe Cell tion as a receptor to initiate a signaling pathway.
Adhesion Activity in PC-3 Cells by C-CAM Recombinant Adenoviruses However, the functional domain(s) of C-CAM1 as a tumor suppressor in prostate cancer is still unknown.
To determine the levels of C-CAM1 expression in Therefore, we decided to analyze the effect of each viral-infected cells, we performed both Northern and domain of the C-CAM1 molecule on the in vivo Western blot assays, as described previously [1] . In growth inhibition of prostate cancer.
Northern blot analysis, a radiolabeled C-CAM cDNA fragment generated from BamHI and PstI digestion was used for probing. For determining C-CAM1 pro-
MATERIALS AND METHODS
tein expression by each clone, cells were infected with Construction and Characterization of virus at 10 m.o.i. for 24 hr. The cell lysate was subRecombinant Adenoviruses Containing C-CAM jected to Western blot analysis using the antibody speDeletion Mutants cific against C-CAM1 [8,9]. Cell adhesion activity in PC-3 cells after adenoviral To generate recombinant adenoviruses containing infection was carried out for determining the func-4 various deletion mutants of C-CAM1 cDNA, the tion of the C-CAM molecule. One million PC-3 cells cDNAs were directionally cloned into the HindIII and were resuspended in a 1.0-ml medium and mixed NotI sites of a shuttle vector (pAdEICMV/pA) and gently at room temperature to allow formation of cotransfected with the pJM17 vector into 293 cells, as cell aggregation. At any given time, cell adhesion described previously [4] . After a large-scale producactivity was determined reciprocally by the pretion using two cycles of CsCl ultracentrifugation, sence of the percentage of single cells counted by a the titer of each virus was determined by the plaque hemacytometer [3] . rying the different C-CAM I deletion constructs were generated from homologous recombination, as described previously [4] . The After viral infection for 18 hr, PC-3 cells were tryp-488 of C-CAM1 was changed to phenylalanine with sinized, and cell numbers were counted by hemacysite-directed mutagenesis PCR, as described previtometer. One million cells were concentrated in a 100-site-d Inect d itione de scribe amilu1 volume and injected subcutaneously at six sites in ously [10] . In addition, we deleted most of the amino the flanks of 8-10-week-old male nude mice. Tumors acids in the intracellular domain to the His-458 posibecame palpable in about 1 month; the change in tution (i.e., AdCAMH458), or removed an additional mor volume was measured by a caliper and calculated four amino acids containing a potential Ser/The usin thlue f las deascred byacaliprevu [3] . caphosphorylation site to the Gly-454 position (i.e., using the formula described previously [3] . AdCAMG454). On the other hand, the first Ig domain of C-CAM1 is known to play an important role in cell RESULTS adhesion function [8]; therefore, a C-CAM1 mutant Generation and Characterization of the containing the first Ig domain deletion (i.e., Recombinant Adenoviruses Carrying Various AdCAMAD1) was created to eliminate its cell adhe-C-CAM I Inserts sion function. Furthermore, two recombinant adenoviruses from a previous study [4] , one containing a To assess the functional domain of C-CAM1 in supsense strand of C-CAM1 cDNA (i.e., AdCAM902) and pressing tumor growth of human prostate cancer cells, the other containing an antisense strand of C-CAM1 we decided to create a variety of C-CAM1 mutants by cDNA (i.e., AdCAM101), were used in this study. altering the potential phosphorylation site or the deWe performed a PCR reaction to determine the leting intracellular domain of the C-CAM1 molecule.
presence of an individual C-CAM1 insert from each As shown in Figure 1 , a single base mutation on Tyradenovirus. As shown in Figure 2A , the size of each PCR product corresponded to that of the individual different clones of viruses at 10 m.o.i. As shown in C-CAM1 mutant. In addition, using a virus-specific Figure 4A , no detectable levels of C-CAM mRNA primer set (Fig. 2B ), we were able to confirm the preswere found in control PC-3 cells. A full-length Cence of viral DNA from each recombinant virus. Fur-CAMI mRNA was detected in PC-3 cells infected with thermore, to rule out any possible contamination from either AdCAM101 or AdCAM902 viruses by a doublewild-type adenovirus in each preparation, we emstranded cDNA probe. In contrast, a variable-sized Cployed a PCR reaction to determine the presence of El CAM mRNA transcript was detected in PC-3 cells insequences in each C-CAM1 adenovirus, using the Elfected with the rest of the C-CAM1 mutant viruses. specific primer set. The data in Figure 2C indicate that Western blot analysis (Fig. 4B ) indicated that both a 1.07-kb specific band was only detected in the wildAdCAM902 and AdCAMF488 expressed a C-CAM1 type adenovirus (i.e., Ad5), and not in C-CAM1 viprotein with 105 kDa. As expected, the molecular ruses and other control viruses such as d1312 with an weight of mutated C-CAM1 protein induced by each El-deletion [11] . mutant virus was smaller than that of wild-type CData from the plaque assay indicated that the titer CAM1 protein (Fig. 4B ). of each virus, ranging from 1 x 1010-4 x 1010 pfu/ml, The cell adhesive assay was used as a functional was very similar. Since the plaque assay was detertest for these deletion mutants. Data in Figure 5 indimined in 293 cells, it is critical to know whether each cate that the control cells and PC-3 cells infected virus has an infectivity similar to that of our target with AdCAM101 did not show any increase in inter-PC-3 cells. As shown in Figure 3B , the FACS results cellular adhesion. However, cells infected with either demonstrated that no C-CAM1 expression was deAdCAM902 or viruses containing the first Ig dotected in the AdCAM101-infected cells, because they main (such as AdCAMF488, AdCAMH458, and expressed the antisense C-CAM1 mRNA. In contrast, AdCAMG454) showed the same degree of cell adhethe numbers of cells infected by each virus at 100 sion function. In contrast, AdCAMAD1, a mutant with m.o.i. (Fig. 3A,C-F) reached a plateau. Therefore, we a deletion of the first Ig domain, failed to elicit any decided to use a lower dose of virus to test its tumor intercellular adhesion in PC-3 cells, indicating that the suppression function and in order to avoid any artifact first Ig domain is critical for the cell adhesive activity due to viral toxicity.
of the C-CAM1 molecule. 
Determination of Expression and Function of

S60-
AdCAM902. AdCAMAD1 showed a decrease in its Z tumor suppression function, which may have been due to the low infectivity evidenced by FACS results 'Mock infection (PBS + 10% glycerol), AdCAM101 (antisense C-CAM1), AdCAM902 (sense C-CAM1 virus), AdCAMF488 (mutated C-CAM1 containing Tyr-488 -4 Phe-488), AdCAMH458 (C-CAM1 deletion mutant containing 458 amino acids), AdCAMG454 (C-CAM1 deletion mutant containing 454 amino acids), and AdCAMAD1 (C-CAM1 mutant containing first Ig domain deletion).
bPercentage of positive cells were determined by FACS analyses. cTumor volume was calculated as described previously [3] ; number represented mean ± SE. don~ly one tumor was observed; therefore, no standard error was calculated.
DISCUSSION
tration prostate [1] or human fetal prostate [2] . These data imply that prostatic epithelial cells may use CIt is known that CAMs play a central role in coor-CAM1 as an intercellular adhesion molecule to dinating tissue development and epithelial cell differachieve their cell-cell communication at this stage. entiation [12] [13] [14] . Moreover, altered CAM expression This observation is supported by the expression of is often associated with carcinogenesis and the metaswild-type C-CAM1 protein in insect cells (i.e., Sf9 tasis of many neoplasms [15] [16] [17] [18] . For example, decells); using a baculoviral vector system resulted in creased expression of E-cadherin, a Ca2+-dependent cell aggregation of Sf9 cells [5] . Upon detailed dissecepithelial cell-specific CAM, is associated with the tion, of the function of four Ig domains of C-CAM1, progression of several neoplasms [15, [19] [20] [21] . Recent Cheung et al. [5] showed that the first Ig domain is data from our laboratory and others demonstrated required for intercellular adhesion of the C-CAM1 that C-CAM1, a Ca 2 +-independent epithelial cellmolecule. specific CAM, can be a potent tumor suppressor in
In addition to the extracellular domain of C-CAM1, prostate cancer [3, 4] , colon carcinoma, and hepatocarthe 71 amino acids of the intracellular domain are also cinoma [22] [23] [24] . Furthermore, a cytogenetic study also required for the adhesion function of C-CAM1 [27] . showed that deletion of the DCC gene, with a similar Among these amino-acid sequences, there are two Ig-like structure as the C-CAM1, is found in colon consensus sequences for both cAMP-dependent kicancer [25] . These data indicate that CAMs play a nase and tyrosine kinase. Also, the putative tyrosine functional role in regulating the carcinogenic process.
phosphorylation site localized in the antigen-receptor C-CAM1 (also named cell-CAM105) is a 105-kDa homology (ARH) motif is known to be essential for cell-surface glycoprotein, first detected as the adhesignal transduction in B-cells [28] . Our recent studies sion molecule mediating hepatocyte aggregation [26] .
from both natural mutants of C-CAM (e.g., C-CAM3) Previously, we observed that the C-CAM1 protein can [27] and deletion mutants generated by site-directed be detected between cell boundaries of nonpolarized mutagenesis [10] further indicated that the potential basal prostate epithelial cells in either prolonged casSer/Thr phosphorylation site (amino acids 455-458) in the intracellular domain, in addition to the first Ig dothe transgene in nontarget cells, causing side effects in main, was also critical for C-CAM's cell adhesion the host. To alleviate the undesired toxicity elicited by function.
adenoviruses, in the prostate, tissue-specific promotLittle is known about the functional domain(s) of ers such as prostate-specific antigen [36] and the pro-C-CAM1 in modulating its tumor suppression activity basin gene [37] should be good candidates. Most imin prostate cancer. Therefore, we decided to generate a portantly, this study demonstrated the critical funcvariety of deletion mutants ranging from the deletion tional domain of C-CAM1 in controlling the in vivo of the first Ig domain to the deletion of the "potential growth of human prostate cancer. Based on these resignal transduction motif" in the intracellular domain sults, C-CAM1 can be further engineered into a "pure" of the C-CAM1 molecule. As shown in Table I, both tumor suppressor by removing unnecessary residues, the first Ig domain and the tyrosine phosphorylation which may increase the therapeutic index for this molsite (i.e., amino acid 488) did not play a significant role ecule. Furthermore, identifying the signal pathway in modulating the suppression function of C-CAM1 in elicited by C-CAM1 in prostate cancer can provide a vivo. Interestingly, H458 lost half of the tumor supnew strategy in fighting this disease. pression activity, suggesting that the C-terminal sequences (i.e., the 61 amino acids adjacent to amino ACKNOWLEDGMENTS acid 458), including ARH domain, may be critical for retaining the tumor suppression function of C-CAM1.
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